BioSpace News Archive

iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer

Preclinical Data Presented at Frontiers in Cancer Immunotherapy 2022 Shows Potent Antibody-Dependent Cellular Cytotoxicity with Afucosylated Plant-Made Molecule

November 10, 2022
·
4 min read
iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants

Data Showing Greater Glycosylation Homogeneity with the FastPharming® System Compared to Traditional Methods to be Presented at PEGS Conference & Expo

November 10, 2022
·
3 min read
Drug Development

AstraZeneca Scraps Three Early-Stage Programs, US COVID-19 Vaccine Efforts

AstraZeneca will give up on seeking approval for its COVID-19 vaccine in the United States. It is also abandoning three early-stage programs.

November 10, 2022
·
2 min read
·
Mark Terry
Drug Development

BrainStorm Denied Again in ALS as FDA Issues Refuse-to-File Letter (Updated)

BrainStorm Cell Therapeutics ran into another stumbling block with ALS hopeful NurOwn Thursday as the FDA issued a Refusal to File Letter for its Biologics License Application.

November 10, 2022
·
2 min read
·
Heather McKenzie
Business

Movers & Shakers: Odyssey, Daiichi Sankyo, Atsena and More

While Biogen and Seagen made the biggest C-suite splashes this week, other companies across the biopharma industry also bolstered their leadership teams with new talent.

November 10, 2022
·
6 min read
·
Alex Keown
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the

November 10, 2022
·
10 min read
Policy

AAV9-Based Gene Therapy for ALS Scores FDA Orphan Drug Nod

A gene therapy being developed by Eikonoklastes Therapeutics to treat ALS received Orphan Drug Designation, the company announced Wednesday.

November 10, 2022
·
3 min read
·
Heather McKenzie
Pharm Country

Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022

Cellectis today announced that preclinical data will be presented on TALEN®-edited smart CAR T-cells overcoming key challenges of targeting solid tumors at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.

November 10, 2022
·
5 min read
Biotech Beach

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, in two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting taking place in Boston.

November 10, 2022
·
8 min read
Drug Development

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study’s Pancreatic Cancer Cohort

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study’s first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort.

November 10, 2022
·
9 min read